The Medical Letter on Drugs and Therapeutics
ONLINE
ONLY
ARTICLE
July 22, 2024
View Complete Issue         Table of Contents 2019 
Nifurtimox (Lampit) for Chagas Disease (online only)
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Nifurtimox (Lampit) for Chagas Disease (online only)
July 22, 2024 (Issue: 1707)
The FDA has approved the nitrofuran antiprotozoal drug nifurtimox (Lampit – Bayer) for treatment of Chagas disease (American trypanosomiasis) in children who weigh ≥2.5 kg. Nifurtimox was previously available in the US only through a...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Nifurtimox (Lampit) for Chagas Disease (online only)
Article code: 1707h
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.